Related Experiment Videos
Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy
K Wakabayashi1, M Yoshimoto, S Tsuji
1Brain Disease Research Center, Brain Research Institute, Niigata University, Japan. koichi@bri.niigata-u.ac.jp
Neuroscience Letters
|July 31, 1998
Summary
Alpha-synuclein is a key component in both Parkinson's disease (PD) and multiple system atrophy (MSA). This study found alpha-synuclein in glial cytoplasmic inclusions unique to MSA, suggesting a common aggregation process in these neurodegenerative diseases.
Area of Science:
- Neuroscience
- Pathology
- Biochemistry
Background:
- Lewy bodies in Parkinson's disease (PD) show strong immunoreactivity to alpha-synuclein.
- Alpha-synuclein gene mutations are linked to familial forms of PD.
- Multiple system atrophy (MSA) is a neurodegenerative disorder characterized by distinct pathological inclusions.
Purpose of the Study:
- To investigate the presence and distribution of alpha-synuclein in the brains of patients with multiple system atrophy (MSA).
- To compare alpha-synuclein pathology in MSA with that observed in Parkinson's disease.
- To determine if alpha-synuclein aggregation is a shared mechanism in both PD and MSA.
Main Methods:
- Immunohistochemical examination of brain tissue from MSA patients.
- Utilized antibodies specific to alpha-synuclein.
- Examined specific brain regions including the substantia nigra, pontine and inferior olivary nuclei, and dentate fascia.
Main Results:
- Strong alpha-synuclein immunoreactivity was detected in glial cytoplasmic inclusions (GCIs) exclusively found in MSA.
- GCIs are of oligodendroglial origin.
- Alpha-synuclein-immunoreactive neuronal cytoplasmic inclusions (NCIs) were occasionally observed in specific neuronal populations.
Conclusions:
- Alpha-synuclein is a major component of both GCIs in MSA and Lewy bodies in PD.
- The findings strongly suggest that alpha-synuclein aggregation is a common pathological process in neurodegenerative diseases like PD and MSA.
- This highlights alpha-synuclein as a potential common therapeutic target for these conditions.